Please login to the form below

Not currently logged in
Email:
Password:

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  
 FDA building

The US FDA has approved Bristol-Myers Squibb's Evotaz in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Evotaz combines BMS' Reyataz (atazanavir) with Gilead Science's boosting agency cobicistat as part of a once-daily pill to be taken over a 48-week course.

The treatment is the outcome of an agreement made between BMS and Gilead in 2011, when they agreed to develop and market a fixed-dose combination HIV treatment

Murdo Gordon, head of worldwide markets at BMS, commented: “Evotaz increases the possibility of providing HIV suppression by combining reduced pill burden with a low rate of virologic failure and zero protease inhibitor mutations.”

Cobicistat is already a crucial part of several HIV treatments, including Rezolsta/Prezcobix, which pairs the drug with Janssen's Prezista (darunavir), and Gilead's own combination therapy Stribild.

Reyataz is also a successful monotherapy treatment for HIV managing worldwide revenues of more than $1bn for the first nine months of 2014.

BMS is responsible for the manufacturing and sale of the cobicistat-boosted eyataz product and will pay Gilead royalties on sales.

 

Article by
Kirstie Pickering

2nd February 2015

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...
Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...

Infographics